GET THE APP

Journal of Clinical Toxicology

Journal of Clinical Toxicology
Open Access

ISSN: 2161-0495

+44 2038689735

Masood A. Shammas

Masood A. Shammas

Masood A. Shammas
Lead Scientist, Department of Medical Oncology, Harvard (Dana Farber) Cancer Institute
Harvard University, United States

Biography

Dr. Masood A. Shammas currently working as a Lead Scientist at Dana Farber Cancer Institute, Boston, USA. He obtained my doctorate in Biochemistry and Molecular Biology from University of Arkansas for Medical Sciences, Little Rock, AR, USA and continued in the same department for postdoctoral training. Subsequently, through collaboration, He also joined Myeloma Transplantation Research Center at Arkansas Cancer Research Center. In 1999, He was promoted to the position of Instructor at UAMS. From 2001-2006, He worked as Instructor at Harvard Medical School and Harvard (Dana Farber) Cancer Institute, Boston, USA. In 2006, He accepted a position as Director, Surgical Oncology and Developmental Therapeutics Laboratory and Assistant Professor of Surgery at Wayne State University and Karmanos Cancer Institute, Detroit, USA. While at Detroit, in 2008, He obtained my first R01 award from NCI to explore telomerase and homologous recombination as targets in Barrett’s adenocarcinoma. In 2009, He moved back to Harvard (Dana Farber) Cancer Institute, Boston, USA.

Research Interest

Translational Cancer Research, Environmental and Genomic Toxicology

1) Understanding mechanisms of genomic instability, clonal evolution and oncogenesis; 2) Identification of novel targets and then small molecules to target mechanisms driving genomic evolution (associated with cancer progression) and growth of cancer cells; 3) Developing novel functional assays, suited for high throughput screening of lentiviral and chemical libraries, to monitor activities of specific mechanisms of genomic instability/evolution; 4) Evaluating diagnostic/prognostic significance of these assays; 5) Identifying potential risks and compliance issues with attempt to increase public awareness, develop methods for risk assessment and design strategies to minimize exposure as well as reduce genomic toxicity of chemotherapeutic agents.

Top